Anticancer agent 360

Anticancer agent 360 (compound 13) (2-64 µg/mL; 24-30 h) exhibits potent and broad-spectrum antimicrobial activity against all tested reference bacterial and fungal strains, with its MIC against Staphylococcus aureus ATCC 9144 as low as 2 µg/mL^[1].
Anticancer agent 360 (5-100 µg/mL; 48 h) reduces the viability of HepG2 cells at high concentrations, exhibiting selective cytotoxic activity against HepG2 hepatocellular carcinoma cells^[1].
Anticancer agent 360 (0.25-0.8 MIC; 2-4 h) eliminates preformed P. aeruginosa ATCC 27853 biofilms in a dose- and time-dependent manner^[1].
Antineoplastic agent 360 (0.25-0.8 MIC; 2-4 h) effectively inhibits the activity of respiratory chain dehydrogenase in P. aeruginosa ATCC 27853 biofilms, and this effect exhibits a concentration- and time-dependent manner in vitro^[1].
Anticancer agent 360 exhibits strong binding affinity for the ATP-binding pockets of DNA gyrase from both E. coli and S. aureus, and can form stable salt bridge interactions with key active-site residues, with its relative affinity for the S. aureus enzyme being higher than that of the co-crystallized ligand^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.